Anti-Human KLRC1 Recombinant Antibody (TAB-437CQ)

Customer Review

There are currently no Customer reviews or questions for TAB-437CQ. Click the button above to contact us or submit your feedback about this product.

Emily Roberts
18.Feb,24

Great for Immune Studies

The Monalizumab has been a fantastic addition to our immune cell studies. Its specificity and sensitivity are outstanding, consistently providing clear results. This antibody has become essential for our research, improving the accuracy and reliability of our assays.

James Wilson
30.Jun,23

Effective in Flow Cytometry

We incorporated this antibody into our flow cytometry experiments, and it's been a great asset. The specificity for target cells is precise, allowing for accurate cell population analysis. The reliable performance has made it an invaluable tool in our lab.

Laura Lee
17.Oct,22

Consistent and Reliable

This antibody has proven to be consistent and reliable in our immunoassays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for its target have been particularly beneficial.

Q&As

1. Can Monalizumab be used in in vitro assays to study NK cell activity?

   A: Yes, Monalizumab (TAB-437CQ) can be used in in vitro assays to study NK cell activity. It is specifically designed to target NK cells, making it a valuable tool for such studies.

2. What are the storage recommendations for Monalizumab to maintain its stability?

   A: The recommended storage condition for Monalizumab (TAB-437CQ) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, it should be stored in aliquots to avoid repeated freeze-thaw cycles.

3. Is Monalizumab effective in blocking NKG2A receptor-ligand interactions in vitro?

   A: Yes, Monalizumab (TAB-437CQ) is effective in blocking NKG2A receptor-ligand interactions in vitro. It has been validated for use in such assays and can inhibit the interaction between NKG2A and its ligands, which is important for studying immune regulation mechanisms.

4. Can Monalizumab be used in flow cytometry analysis?

   A: Yes, Monalizumab (TAB-437CQ) can be used in flow cytometry analysis. It is specifically designed to bind to its target, making it suitable for detecting target-expressing cells in flow cytometry.

5. What is the optimal dilution for using Monalizumab in Western blotting?

   A: The optimal dilution for using Monalizumab (TAB-437CQ) in Western blotting is typically 1:500 to 1:2000. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Battin, Claire, et al. "NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E." Immunology 166.4 (2022): 507-521. https://doi.org/10.1111/imm.13515
   This study investigates the dependence of NKG2A-checkpoint inhibition and its blockade on peptides presented by its ligand HLA-E. Researchers evaluated how different HLA-E-bound peptides impact the inhibitory signaling of NKG2A and the efficacy of monalizumab, a novel immune checkpoint inhibitor (ICI) targeting NKG2A. They found that various peptides derived from the leader sequences of classical MHC class I molecules and the non-classical class I paralogue HLA-G mediate different levels of NKG2A inhibition. The study shows that monalizumab's effectiveness in enhancing NK and CD8+ T cell responses depends significantly on the specific peptide presented by HLA-E, with peptides from HLA-G being less effectively blocked compared to those from HLA-A, HLA-B, and HLA-C.
   At Creative Biolabs, we contributed to this critical research by supplying the therapeutic NKG2A antibody monalizumab (Cat#: TAB-437CQ) used in the study to assess its binding and blocking capacities. Our product was essential in demonstrating that monalizumab's efficiency in blocking NKG2A-mediated inhibition varies with different HLA-E-bound peptides. This research highlights the importance of peptide-HLA-E interactions in determining the success of NKG2A-targeted immunotherapies, showcasing our commitment to advancing cancer immunotherapy research and developing innovative therapeutic solutions.
2. Choi, Seong Jin, et al. "KIR+ CD8+ and NKG2A+ CD8+ T cells are distinct innate-like populations in humans." Cell Reports 42.3 (2023). https://doi.org/10.1016/j.celrep.2023.112236
   This study explores the heterogeneity among human KIR+CD8+ and NKG2A+CD8+ T cells, identifying them as distinct innate-like populations with different cytokine responsiveness. The research demonstrates that KIR+CD8+ T cells exhibit IL-15-induced NK-like cytotoxicity, while NKG2A+CD8+ T cells show IL-12/IL-18-induced IFN-gamma production. It was observed that KIR+CD8+ T cells are more terminally differentiated and replicative senescent compared to NKG2A+CD8+ T cells, which are more responsive to IL-12 and IL-18 due to the high expression of these receptors induced by the transcription factor PLZF.
   At Creative Biolabs, we provided essential reagents for this study, including the anti-NKG2A antibody (Cat#: TAB-437CQ) and the IgG4 isotype control (Cat# MOB-0408ZL) used in the flow cytometry analyses. Our products were crucial in identifying the distinct functional roles and cytokine responses of these T cell subsets. This research underscores the importance of understanding the diverse functions of T cell populations in developing targeted immunotherapies, highlighting our commitment to advancing immunological research and innovative therapeutic solutions.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-437CQ, RRID: AB_3111944)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Monalizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Monalizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "KLRC1"

Select a product category from the dropdown menu below to view related products.